Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with High-Dose Ibrutinib in Ibrutinib-Resistant CLL/SLL
NCT03422393Phase 1Active, not recruiting
- Start
- May 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax and ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoints: Dose Limiting Toxicities at 35 days and Maximum Tolerated Dose at 1 year. Started May 2018; status: active, not recruiting.
02
Drugs
venetoclaxibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03422393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422393.